ライフサイエンスコーパス: early cancer

1 nagement of large flat colorectal polyps and early cancer.

2 nded to detect high-grade dysplasia (HGD) or early cancer.

3 accuracy, identify tumor margins, and stage early cancers.

4 to the development of novel tests to detect early cancers.

5 Tests that can detect both early cancer and cancer precursor lesions include sigmoi

6 invasive and may result in detection of both early cancer and cancer precursor lesions.

7 een shown to visualize capillary patterns in early cancer and is complementary to magnification endos

8 could prove vital for the identification of early cancer and people at risk of developing cancer.

9 ledge about how these screening tests detect early cancer and polyps and assess factors that influenc

10 aoperative imaging and enhanced detection of early cancers and metastases.

11 are being shown to enhance the detection of early cancers and precancerous lesions.

12 Early cancers are avascular and hence, profoundly acidic

13 e for the detection of l-lactate as a viable early cancer bio-marker.

14 ta will be instrumental in identifying novel early cancer biomarkers and could provide a rationale fo

15 hnology platforms to facilitate detection of early cancer by means of biomarkers, and issues on the a

16 Early cancer cell dissemination followed by a protracted

17 er2(+)p-p38(lo)p-Atf2(lo)Twist1(hi)E-cad(lo) early cancer cells that is invasive and can spread to ta

18 to genome instability of precancerous and/or early cancer cells.

19 cient to generate at least two phenotypes of early cancer cells: genomic instability that involves mu

20 creening test that primarily is effective at early cancer detection and a screening test that is effe

21 duals can result in mortality reduction with early cancer detection and cancer prevention by detectio

22 d a screening test that is effective at both early cancer detection and cancer prevention through the

23 nt that has been clinically demonstrated for early cancer detection and guidance of therapy.

24 ly aid in screening prospective patients for early cancer detection and in monitoring the efficacy of

25 f tumor initiation has significant impact on early cancer detection and intervention.

26 oduct can potentially be used for screening, early cancer detection and patient stratification.

27 Early cancer detection and treatment is an emerging and

28 oodstreams of cancer patients are pivotal to early cancer detection and treatment monitoring.

29 tic probe, this platform can pave the way to early cancer detection and treatment.

30 Early cancer detection currently relies on screening the

31 Early cancer detection has always been a major research

32 oking cessation interventions, screening and early cancer detection in HIV-infected populations are o

33 This opens the possibility to develop an early cancer detection test based on a set of peptide se

34 tile properties with nano-biosensors towards early cancer detection to preserve human health.

35 Thus early cancer detection via PPi recognition in physiologi

36 band imaging have a 77-99.4% sensitivity for early cancer detection, a significant improvement when c

37 ulating nucleic acids in prenatal diagnosis, early cancer detection, and the diagnosis of infectious

38 edical applications including ophthalmology, early cancer detection, and understanding fundamental di

39 loser to the clinic where it can be used for early cancer detection, disease characterization and gui

40 RG variants are potentially useful to aid in early cancer detection, immediate patient risk stratific

41 w-proportion tumor subclones can be used for early cancer detection, prognostic assessment and therap

42 gery with a slight compromise in the rate of early cancer detection.

43 dentification of low frequency mutations for early cancer detection.

44 r harnessing the humoral immune response for early cancer detection.

45 tages of cancer, with promising findings for early cancer detection.

46 ical samples hold great promise for reliable early cancer detection.

47 developed to quantify nuclear morphology for early cancer detection.

48 evelopment of noninvasive clinical tests for early cancer detection.

49 rker discovery and provide new insights into early cancer detection.

50 ctrometry is a potentially powerful tool for early cancer detection.

51 Identification of early cancer, detection of progression, and monitoring o

52 thelial cell apical-basal polarity occurs in early cancer development and is often correlated with in

53 The role of adaptive immunity in early cancer development is controversial.

54 n of cancer genes and occur predominantly in early cancer development rather than the later stages of

55 Despite its potential importance in early cancer development, the precise nature of oncogene

56 s in promoter regions acts as a precursor to early cancer development.

57 differentiation and CD11b(+)Ly6G(+) IMCs in early cancer development.

58 e availability of the reviewed platforms for early cancer diagnosis and the approval of methylation i

59 IR-fluorescence enhancement microarrays, for early cancer diagnosis and therapeutic monitoring.

60 ancy and that early recognition is vital for early cancer diagnosis and treatment.

61 bundant DNA point mutations is essential for early cancer diagnosis and/or prognosis.

62 se genes could provide a powerful method for early cancer diagnosis as well as insight into mechanism

63 related autoantibodies provides a means for early cancer diagnosis as well as leads for therapy.

64 related autoantibodies provides a means for early cancer diagnosis as well as leads for therapy.

65 eloped in this work show its suitability for early cancer diagnosis based on miRNA as a biomarker.

66 RNAs in biomedical field with an emphasis on early cancer diagnosis by overviewing both research base

67 Early cancer diagnosis is critical for the prevention of

68 Early cancer diagnosis remains the holy-grail in the bat

69 ne (considered as an excellent biomarker for early cancer diagnosis) with a detection limit of 66 ppb

70 associated molecules could be beneficial for early cancer diagnosis, monitoring and surveillance.

71 s great promise for its translational use in early cancer diagnosis, prognostic assessment of tumor b

72 and is likely to have great significance in early cancer diagnosis.

73 methylation, which is closely correlated to early cancer diagnosis.

74 improved public health monitoring and aid in early cancer diagnosis.

75 This complex represents a potentially new early cancer diagnostic for detecting deficiencies in mi

76 considered as an important tumor marker for early cancer diagnostics.

77 lude that MT1-MMP plays an important role in early cancer dissemination by converting epithelial cell

78 sed mutagenesis allows the identification of early cancer drivers, but current sequencing methods hav

79 ntigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials.

80 py is frequently used to treat dysplasia and early cancers in Barrett's esophagus.

81 of MRI to identify potential precancerous or early cancers in individuals at risk for pancreatic canc

82 logy and techniques, the future treatment of early cancers in the upper gastrointestinal tract may be

83 Tests that primarily detect early cancer include sensitive guaiac fecal occult blood

84 ithelial AR serves as a tumour suppressor in early cancer initiation.

85 the pretest probability that a biomarker of early cancer is a true positive and warrants further inv

86 The most significant development for staging early cancers is mucosal resection.

87 a histologic marker in the identification of early cancer of the gastric stump.

88 copic mucosal resection (EMR) of superficial early cancers of the upper gastrointestinal tract is sta

89 endoscopic mucosal resection of superficial early cancers of the upper gastrointestinal tract.

90 issues reflective of low malignant potential/early cancer onset and possible pre-cancerous stages inv

91 ssues reflective of low potential malignancy/early cancer onset stages via long distance signaling be

92 Bloom syndrome is a disorder of profound and early cancer predisposition in which cells become hyperm

93 circulating metabolites are associated with early cancer progression is unknown.

94 from patients with shorter survival time or early cancer recurrence.

95 l translational potentials as biomarkers for early cancer screening, diagnostic and/or therapeutic in

96 ce to health care, which may be a barrier to early cancer screening.

97 cally difficult to use as a routine tool for early cancer screening.

98 Median cancer size and the percentage of early cancers showed little change with any factors.

99 pecific outcomes (eg, recurrence pattern and early cancer-specific mortality) were determined.

100 subjects at high risk for cancer, to detect early cancer, to detect the early recurrence of establis

101 s a potential tumor-suppressive mechanism in early cancer transitions.

102 nobiosensors are to explore the efficacy for early cancer tumour detection or single molecular detect

103 at multiple stages of gastric dysplasia and early cancer with FA supplementation initiated both at w

104 y, which allows gastroenterologists to treat early cancers with greater confidence regarding rates of